APR 19 2004 PATENT & TRADEMARK OFFICE

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00398-148001	Application No. 10/678,355
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Georg F. Weber	
		Filing Date October 2, 2003	Group Art Unit 1642

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	AD	W0 88/09810	Dec. 15, 1988	WIPO				
	AE	W0 89/10134	Nov. 2, 1989	WIPO				
	AF							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AG	Agnihotri *et al.*, "Osteopontin, a Novel Substrate for Matrix Metalloproteinase-3 (Stromelysin-1) and Matrix Metalloproteinase-7 (Matrilysin)," *J. Biol. Chem.* 276(3):28261-28267 (2001)
	AH	Bartel and Szostak, " Isolation of a new ribozymes from a large pool of random sequences," *Science* 261:1411-1418 (1993)
	AI	Bautista *et al.*, "Inhibition of Arg-Gly-Asp (RGD)-mediated Cell Adhesion to Osteopontin by a Monoclonal Antibody against Osteopontin," *J. Biol. Chem.* 269(37):23280-23285 (1994)
	AJ	Behrend *et al.*, "Reduced Malignancy of *ras*-transformed NIH 3T3 Cells Expressing Antisense Osteopontin RNA," *Cancer Res.* 54:832-837 (1994)
	AK	Behrend *et al.*, "Expression of Antisense Osteopontin RNA in Metastatic Mouse Fibroblasts Is Associated with Reduced Malignancy," *Ann. NY Acad Sci.* 760:299-301 (1995)
	AL	Brown *et al.*, " Osteopontin expression and distribution in human carcinomas," *Am. J. Pathol.* 145:610-623 (1994)
	AM	Chambers *et al.*, "Adhesion of Metastatic, *ras*-transformed NIH 3T3 Cells to Osteopontin, Fibronectin, and Laminin," *Cancer Res.* 53:701-706 (1993)
	AN	Crawford *et al.*, "Distinct roles of Osteopontin in Host Defense Activity and Tumor Survival During Squamous Cell Carcinoma Progression *in Vivo*," *Cancer Res.* 58:5206-5215 (1998)
	AO	Denhardt and Chambers, "Overcoming Obstacles to Metastasis - Defenses Against Host Defenses: Osteopontin (OPN) as a Shield Against Attack by Cytotoxic Host Cells," *J. Cell Biol.* 56:48-51 (1994)
	AP	Fedarko *et al.*, "Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated Attack," *J. Biol. Chem.* 275:16666-16672 (2000)
	AQ	Feng *et al.*, "Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme," *Clin. Exp. Metastasis* 13:453-462 (1995)

Examiner Signature	Date Considered
	5/10/05

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APR 19 2004
PATENT & TRADEMARK OFFICE

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00398-148001	Application No. 10/678,355
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Georg F. Weber	
		Filing Date October 2, 2003	Group Art Unit 1642

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
BF	AR	Fisher and Fedarko, "An Introduction to the SIBLING Family of Proteins," *NIDCR, NIH*, 3rd ICORP meeting (2002)
	AS	Gautier *et al.*, " Alpha-DNA. IV: Alpha-anomeric and beta-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding," *Nucleic Acids Res.* 15:6625-6641 (1987)
	AT	Helfrich *et al.*, "Rat Osteoclasts Adhere to a Wide Range of RGD (Arg-Gly-Asp) Peptide-Containing Proteins, Including the Bone Sialoproteins and Fibronectin, via a β_3 Integrin," *J. Bone Min. Res.* 7:335-343 (1992)
	AU	Inoue *et al.*, "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides," *Nucleic Acids Res.* 15:6131-6148 (1987)
	AV	Inoue *et al.*, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H.," *FEBS Lett.* 215:327-330 (1987)
	AW	Jain *et al.*, " Three SIBLINGs (Small Integrin-Binding LIand, N-linked Glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack," *J Biol. Chem.* 277:13700-8 (2002)
	AX	Kasugai *et al.*, "Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter," *Bone Miner.* 13:235-250 (1991)
	AY	Kiefer *et al.*, "The cDNA and derived amino acid sequence for human osteopontin," *Nucleic Acids Res.* 17:3306 (1989)
	AZ	Kolaskar and Tongaonkar, "A semi-empirical method for prediction of antigenic determinants on protein antigens," *FEBS Letters* 276:172-174 (1990)
	AAA	Kon *et al.*, "Antibodies to Different Peptides in Osteopontin Reveal Complexities in the Various Secreted Forms," *J. Cell. Biol.* 77:487-498 (2000)
	ABB	Lemaitre *et al.*, " Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site," *Proc. Natl. Acad. Sci. USA* 84:648-652 (1987)
	ACC	Letsinger *et al.*, " Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture," *Proc. Natl. Acad. Sci. USA* 86:6553-6556 (1989)
	ADD	Liu *et al.*, "Identification of a Novel Serine Protease-like Gene, the Expression of Which is Down-Regulated during Breast Cancer Progression," *Cancer Res.* 56:3371-3379 (1996)
	AEE	Marchuk *et al.*, " Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products," *Nucleic Acids Res.* 19:1154 (1991)
	AFF	McCawley and Matrisian, " Matrix metalloproteinases: multifunctional contributors to tumor progression," *Mol. Med. Today* 6: 149-156 (2000)
	AGG	Osborne *et al.*, " Aptamers as therapeutic and diagnostic reagents: problems and prospects," *Curr. Opin. Chem. Biol.* 1:5-9 (1997)
	AHH	Patel, " Structural analysis of nucleic acid aptamers," *Curr. Opin. Chem. Biol.* 1:32-46 (1997)
	AII	Ratsch *et al.*, "Multiple Genetic Changes are Required for Efficient Immortalization of Different Subtypes of Normal Human Mammary Epithelial Cells," *Radiation Res.* 155:143-150 (2001)
BF	AJJ	Rittling and Feng, "Detection of Mouse Osteopontin by Western Blotting," *Biochem. Biophys. Res. Comm.* 250:287-292 (1998)

Examiner Signature	Date Considered
Brandon Fetterolf	5/01/05

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00398-148001	Application No. 10/678,355
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Georg F. Weber	
	Filing Date October 2, 2003	Group Art Unit 1642

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
BF	AKK	Rittling *et al.*, " Tumor-derived osteopontin is soluble, not matrix associated," *J. Biol. Chem.* 277:9175-9182 (2002)
	ALL	Saitoh *et al.*, "Expression of Osteopontin in Human Glioma Its Correlation with the Malignancy," *Laboratory Investigation* 72:55-63 (1995)
	AMM	Saitoh, "Human mRNA for OPN-a," GenBank Accession No. D28759, February 7, 1999.
	ANN	Saitoh, "Human mRNA for OPN-b," GenBank Accession No. D28760, February 7, 1999.
	AOO	Saitoh, "Human mRNA for OPN-c," GenBank Accession No. D28761, February 7, 1999.
	APP	Senger and Perruzzi, "Secreted Phosphoprotein Markers for Neoplastic Transformation of Human Epithelial and Fibroblastic Cells," *Cancer Res.* 45:5818-5823 (1985)
	AQQ	Shanmugam *et al.*, " Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells," *Biochem* 36:5729-5738 (1997)
	ARR	Thalmann *et al.*, "Osteopontin: Possible Role in Prostate Cancer Progression," *Clinical Cancer Res.* 5:2271-2277 (1999)
	ASS	Tuschl *et al.*, "Targeted mRNA degradation by double-stranded RNA *in vitro*," *Genes & Dev.* 13:3191-3197 (1999)
	ATT	van der Krol *et al.*, "Modulation of eukaryotic gene expression by complementary RNA or DNA sequences," *BioTechniques* 6:958-976 (1988)
	AUU	Weber and Ashkar, "Stress response genes: the genes that make cancer metastasize," *J. Mol. Med.* 78:404-408 (2000)
	AVV	Weber, "The metastasis gene osteopontin: a candidate target for cancer therapy," *Biochimica et Biophysica Acta* 1552:61-85 (2001)
BF	AWW	Zon, "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," *Pharm. Res.* 5:539-549 (1988)
	AXX	
	AYY	

Examiner Signature	Date Considered
Brenda Fratta	5/24/05

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.